Clinical Trial Update: Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) [Phase 2]

View source ↗

Summary

Open-label extension study to assess long-term safety and efficacy of alirocumab in heterozygous familial hypercholesterolemia completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2020-08-05